Provided by Tiger Fintech (Singapore) Pte. Ltd.

EyePoint

8.94
+0.69008.36%
Post-market: 8.940.00000.00%19:57 EDT
Volume:910.39K
Turnover:8.06M
Market Cap:615.18M
PE:-3.69
High:9.09
Open:8.32
Low:8.27
Close:8.25
Loading ...

EyePoint Pharmaceuticals Price Target Maintained With a $22.00/Share by HC Wainwright & Co.

Dow Jones
·
30 May

EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities

TIPRANKS
·
29 May

J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
28 May

BRIEF-Eyepoint Completes Enrollment In Pivotal Phase 3 Lugano Trial Of Duravy For Treatment Of Wet Age-Related Macular Degeneration

Reuters
·
27 May

EyePoint Completes Enrollment for DURAVYU Phase 3 Trial

TIPRANKS
·
27 May

EyePoint Pharmaceuticals Inc - Lucia Phase 3 Trial Expected to Complete Enrollment in 3Q 2025

THOMSON REUTERS
·
27 May

EyePoint Completes Enrollment in Pivotal Phase 3 Lugano Trial of Duravyu™ for Treatment of Wet Age-Related Macular Degeneration

THOMSON REUTERS
·
27 May

Karen L. Zaderej, Director, Reports Acquisition of Common Shares in EyePoint Pharmaceuticals Inc

Reuters
·
20 May

Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating

MT Newswires Live
·
16 May

BRIEF-Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
16 May

EyePoint Pharmaceuticals Inc : Mizuho Cuts Target Price to $26 From $30

THOMSON REUTERS
·
16 May

EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
16 May

Mizuho Securities Remains a Buy on EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
16 May

Director Karen L. Zaderej Reports Acquisition of Common Shares in EyePoint Pharmaceuticals Inc

Reuters
·
16 May

Positive Buy Rating for EyePoint Pharmaceuticals Driven by Clinical Progress and Strong Financial Position

TIPRANKS
·
15 May

EyePoint Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
08 May

EyePoint Pharma’s Promising Q1 2025 Financial Results

TIPRANKS
·
08 May

EyePoint Pharma’s Earnings Call Highlights Positive Momentum

TIPRANKS
·
08 May

EyePoint Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

EyePoint Pharmaceuticals Q1 EPS $(0.65) Beats $(0.66) Estimate, Sales $24.45M Beat $7.98M Estimate

Benzinga
·
07 May